Overview Dividends

(BCPC) Balchem - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0576652004

Microencapsulated Nutrients, Choline Derivatives, Vitamin K2, Sterilization Gases, Propylene Oxide, Chelated Minerals

Specialty Chemicals
Market Cap in USD: 5,016m

IPO / Inception: 1986-06-03
Return 12m vs S&P 500: -15.3%

EPS (Earnings per Share)

EPS CAGR: -46.99%
EPS Trend: -17.6%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 6.25%
Rev. Trend: 76.0%

Last SUE: 1.65
Qual. Beats: 1

Dividends

Dividend Yield	0.62%
Yield on Cost 5y	0.76%
Yield CAGR 5y	10.67%
Payout Consistency	98.2%
Payout Ratio	19.3%

Risk via 5d forecast
Volatility	21.7%
Value at Risk 5%th	33.5%
Relative Tail Risk	-6.21%

Reward TTM
Sharpe Ratio	-0.13
Alpha	-13.50
CAGR/Max DD	0.34

Character TTM
Hurst Exponent	0.534
Beta	0.523
Beta Downside	0.448

Drawdowns 3y
Max DD	23.10%
Mean DD	8.50%
Median DD	8.56%

Description: BCPC Balchem January 08, 2026

Balchem Corporation (NASDAQ: BCPC) manufactures specialty performance ingredients for a broad set of markets-including human nutrition, animal health, and industrial sterilization-through three operating segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.

The Human Nutrition & Health segment supplies spray-dried and emulsified powders, lipid systems, flavor delivery bases, and niche ingredients such as vitamin K2, microencapsulated nutrients, and choline compounds for food, beverage, and supplement applications. The Animal Nutrition & Health segment focuses on microencapsulated feed additives, chelated minerals, MSM, and choline chloride to improve health and milk production in ruminants and monogastric animals. The Specialty Products segment distributes ethylene oxide, ammonia, and propylene oxide for medical device sterilization and pest control, plus single-use canisters and chelated minerals for high-value crops.

Key metrics (FY 2023): revenue ≈ $2.1 billion, operating margin ≈ 12 %, and free cash flow of about $300 million, driven in part by rising demand for functional foods and protein-rich animal products. The specialty chemicals sector is sensitive to raw-material cost inflation and regulatory changes around sterilants, while long-term growth is supported by global trends toward healthier diets and increased food safety standards.

For a deeper dive into BCPC’s valuation metrics and peer comparison, see the ValueRay analysis.

Piotroski VR‑10 (Strict, 0-10) 8.0

Net Income (149.2m TTM) > 0 and > 6% of Revenue (6% = 60.8m TTM)

FCFTA 0.10 (>2.0%) and ΔFCFTA -0.45pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 21.44% (prev 22.98%; Δ -1.53pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.12 (>3.0%) and CFO 201.6m > Net Income 149.2m (YES >=105%, WARN >=100%)

Net Debt (90.7m) to EBITDA (260.1m) ratio: 0.35 <= 3.0 (WARN <= 3.5)

Current Ratio 2.72 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (32.7m) change vs 12m ago -0.25% (target <= -2.0% for YES)

Gross Margin 35.82% (prev 34.47%; Δ 1.35pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 62.22% (prev 59.01%; Δ 3.21pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 18.82 (EBITDA TTM 260.1m / Interest Expense TTM 10.9m) >= 6 (WARN >= 3)

Altman Z'' 7.23

(A) 0.13 = (Total Current Assets 343.7m - Total Current Liabilities 126.4m) / Total Assets 1.66b

(B) 0.67 = Retained Earnings (Balance) 1.11b / Total Assets 1.66b

(D) 3.19 = Book Value of Equity 1.16b / Total Liabilities 363.2m

Total Rating: 7.23 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 73.63

1. Piotroski 8.0pt

2. FCF Yield 3.16%

3. FCF Margin 15.94%

4. Debt/Equity 0.12

5. Debt/Ebitda 0.35

6. ROIC - WACC (= 3.47)%

7. RoE 12.12%

8. Rev. Trend 75.96%

9. EPS Trend -17.65%

What is the price of BCPC shares?

As of January 08, 2026, the stock is trading at USD 154.69 with a total of 141,184 shares traded.
Over the past week, the price has changed by +0.87%, over one month by +5.62%, over three months by +10.24% and over the past year by +0.38%.

Is BCPC a buy, sell or hold?

Balchem has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy BCPC.

Strong Buy: 0
Buy: 2
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the BCPC price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	191	23.5%
Analysts Target Price	191	23.5%
ValueRay Target Price	161.9	4.7%

BCPC Fundamental Data Overview January 01, 2026

Market Cap USD = 5.02b (5.02b USD * 1.0 USD.USD)
P/E Trailing = 33.8206
P/E Forward = 29.9401
P/S = 4.9492
P/B = 3.8568
P/EG = 3.7539
Beta = 0.993
Revenue TTM = 1.01b USD
EBIT TTM = 204.3m USD
EBITDA TTM = 260.1m USD
Long Term Debt = 154.0m USD (from longTermDebt, last quarter)
Short Term Debt = 202.0k USD (from shortTermDebt, last quarter)
Debt = 155.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 90.7m USD (from netDebt column, last quarter)
Enterprise Value = 5.11b USD (5.02b + Debt 155.8m - CCE 65.1m)
Interest Coverage Ratio = 18.82 (Ebit TTM 204.3m / Interest Expense TTM 10.9m)
FCF Yield = 3.16% (FCF TTM 161.6m / Enterprise Value 5.11b)
FCF Margin = 15.94% (FCF TTM 161.6m / Revenue TTM 1.01b)
Net Margin = 14.72% (Net Income TTM 149.2m / Revenue TTM 1.01b)
Gross Margin = 35.82% ((Revenue TTM 1.01b - Cost of Revenue TTM 650.5m) / Revenue TTM)
Gross Margin QoQ = 35.68% (prev 36.45%)
Tobins Q-Ratio = 3.07 (Enterprise Value 5.11b / Total Assets 1.66b)
Interest Expense / Debt = 1.51% (Interest Expense 2.35m / Debt 155.8m)
Taxrate = 22.59% (11.8m / 52.0m)
NOPAT = 158.2m (EBIT 204.3m * (1 - 22.59%))
Current Ratio = 2.72 (Total Current Assets 343.7m / Total Current Liabilities 126.4m)
Debt / Equity = 0.12 (Debt 155.8m / totalStockholderEquity, last quarter 1.30b)
Debt / EBITDA = 0.35 (Net Debt 90.7m / EBITDA 260.1m)
Debt / FCF = 0.56 (Net Debt 90.7m / FCF TTM 161.6m)
Total Stockholder Equity = 1.23b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.98% (Net Income 149.2m / Total Assets 1.66b)
RoE = 12.12% (Net Income TTM 149.2m / Total Stockholder Equity 1.23b)
RoCE = 14.75% (EBIT 204.3m / Capital Employed (Equity 1.23b + L.T.Debt 154.0m))
RoIC = 11.20% (NOPAT 158.2m / Invested Capital 1.41b)
WACC = 7.74% (E(5.02b)/V(5.17b) * Re(7.94%) + D(155.8m)/V(5.17b) * Rd(1.51%) * (1-Tc(0.23)))
Discount Rate = 7.94% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 0.35%
[DCF Debug] Terminal Value 80.77% ; FCFE base≈162.0m ; Y1≈190.6m ; Y5≈291.5m
Fair Price DCF = 154.3 (DCF Value 5.00b / Shares Outstanding 32.4m; 5y FCF grow 18.81% → 3.0% )
EPS Correlation: -17.65 | EPS CAGR: -46.99% | SUE: -4.0 | # QB: 0
Revenue Correlation: 75.96 | Revenue CAGR: 6.25% | SUE: 1.65 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.31 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=5.57 | Chg30d=+0.048 | Revisions Net=+1 | Growth EPS=+9.0% | Growth Revenue=+6.4%

Additional Sources for BCPC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle